Tomato containing high-concentration 7-dehydrocholesterol and production method thereof
Through CRISPR technology, the DWF5-1, CPD and SMT1 genes are missing, and the accumulation of medium and high concentrations of 7-dehydrocholesterol in tomatoes is solved, and the problem of difficulty in obtaining vitamin D when there is insufficient sunlight is provided. It provides food resources rich in vitamin D3, and has commercial applicability.
Patent Information
- Application Number
- CN202380030161.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-24
- Filing Date
- 2023-01-25
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to meet the daily vitamin D needs through food intake, especially when sunlight is insufficient, natural vitamin D is difficult to obtain and synthetic vitamin D has side effects, and food resources rich in vitamin D3 are lacking.
The DWF5-1, CPD and SMT1 genes were deleted by CRISPR technology, and the vector was introduced into tomatoes using Agrobacterium to achieve the accumulation of medium and high concentrations of 7-dehydrocholesterol in tomatoes, thus serving as a precursor to vitamin D3.
The successful production of converted tomatoes containing high concentrations of 7-dehydrocholesterol ensures a rich supply of vitamin D3 precursors, and the growth and seed production of converted tomatoes are similar to those of wild type and are industrially practical.
Smart Images

Figure CN119031835A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a tomato containing high concentration of 7-dehydrocholesterol (precursor of vitamin D3) and a production method thereof. Background Art
[0002] Vitamin D is an essential nutrient for maintaining life. It is reported that vitamin D deficiency not only increases the incidence of rickets, osteomalacia, and osteoporosis, but also increases the incidence of malignant tumors such as breast cancer, colorectal cancer, and prostate cancer; cardiovascular diseases including hypertension; diabetes; multiple sclerosis; psoriasis; rheumatoid arthritis; tuberculosis, etc. Vitamin D is a vitamin that can be ingested through food, but can also be synthesized in the body through sufficient sunlight. Therefore, if you lack sufficient sunlight exposure, you should consume foods rich in vitamin D or supplement with vitamin D nutritional supplements.
[0003] In particular, modern people spend most of the day indoors, and even when they are outdoors, they use clothes and hats to block the sun, so they need to pay attention to the lack of vitamin D. In the case of insufficient sunlight, it is necessary to take in enough vitamin D through food, but there is a problem that there are not many foods with high vitamin D content. Even though it is known that foods are rich in vitamin D, the amount of vitamin D contained in 100 grams of food is: 0.29μg / about 7 slices (about 100g) of cheese slices, 2.9μg / 100g of tuna, 1.36μg / 2 eggs (about 100g), 4.4μg / about 1 cup (about 100g) of raisins. Therefore, it is impossible to meet the daily recommended intake of vitamin D from these foods.
[0004] In addition, as a nutritional supplement of vitamin D, synthetic vitamin D is reported to have side effects and adverse reactions, while natural vitamin D has the problem of being very expensive and difficult to obtain. On the other hand, Korean Patent Publication No.: 10-2017-0138657 discloses that when DWF5 (δ5,7-sterol δ7 reductase, DWARF5), CPD (constitutive photomorphogen DWAF, DWF3) and SMT1 (sterol methyltransferase 1) genes are deleted, lettuce rich in 7-dehydrocampesterol, a precursor of vitamin D, can be produced. However, there is no research on the production of tomatoes rich in 7-dehydrocholesterol, a precursor of vitamin D3. Summary of the invention
[0005] Technical issues
[0006] Therefore, the inventors conducted experiments by deleting the DWF5-1, CPD and SMT1 genes using CRISPR technology. The results confirmed that when the DWF5-1 gene was deleted, tomatoes containing high concentrations of 7-dehydrocholesterol were produced. Based on the above, the inventors completed the present invention. Specifically, the present invention aims to determine the DWF5-1, CPD and SMT1 deletion sites optimized for the development of tomatoes containing high concentrations of 7-dehydrocholesterol (a precursor for the production of vitamin D3), and to develop tomatoes rich in vitamin D3 precursors containing them.
[0007] Solution
[0008] In order to achieve the above object, in one aspect of the present invention, a transformed tomato containing a high concentration of 7-dehydrocholesterol of the following formula 1 is provided.
[0009] In another aspect of the present invention, a vector is provided, which comprises one or more sgRNAs (single-stranded guide RNAs) that complementarily bind to the nucleotide sequence of the DWF5-1 gene and a nucleotide sequence encoding a CRISPR (clustered regularly interspaced palindromic repeats)-related protein.
[0010] In another aspect of the present invention, a method for producing transformed tomatoes containing high concentrations of 7-dehydrocholesterol is provided, comprising introducing a vector into tomatoes using Agrobacterium.
[0011] Effects of the Invention
[0012] When the transformed tomato produced according to the present invention is homozygous for the DWF5-1 gene mutation, the fruit and roots of the tomato accumulate a large amount of 7-dehydrocholesterol. In addition, the homozygote (T2) is able to produce seeds, thereby retaining the desired tomato characteristics. Therefore, the transformed tomato of the present invention has high commercial applicability. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 is a diagram showing the DWF5-1 site targeted by DWF5-1 sgRNA.
[0014] Figure 2 is a diagram showing the CPD site targeted by CPD sgRNA.
[0015] Figure 3 is a diagram showing the SMT1 site targeted by SMT1 sgRNA.
[0016] Figure 4 The figure shows the results obtained by confirming the gene editing efficiency of DWF5-1 sgRNA using RGEN.
[0017] Figure 5The figure shows the results obtained by confirming the CPD gene editing efficiency of CPD sgRNA using RGEN.
[0018] Figure 6 The figure shows the results obtained by confirming the SMT1 gene editing efficiency of SMT1 sgRNA using RGEN.
[0019] Figure 7 A schematic diagram of the Cas9-sgRNA vector loaded with DWF5-1 sgRNA is shown.
[0020] Figure 8 A schematic diagram of the Cas9-sgRNA vector loaded with DWF5-1 sgRNA and CPD sgRNA is shown.
[0021] Fig. 9 A schematic diagram of the Cas9-sgRNA vector loaded with DWF5-1 sgRNA, CPD sgRNA, and SMT1 sgRNA is shown.
[0022] Fig.10 is a flow chart showing the process of transforming tomato using Agrobacterium constructs.
[0023] Fig.11 Shown is the germination process of a tomato created through gene editing.
[0024] Fig.12 The figure shows the results of observation of tomato plants in which the DWF5-1 gene was edited.
[0025] Fig.13 The graph shows the results of observation of tomato plants in which the DWF5-1 and CPD genes were edited.
[0026] Fig.14 The graph shows the results of observation of tomato plants in which the DWF5-1, CPD, and SMT1 genes were edited.
[0027] Fig.15 The graph shows the results obtained by confirming whether the DWF5-1, CPD, or SMT1 gene was edited using the T7E1 assay.
[0028] Fig.16 The figure shows the results of confirming whether the DWF5-1 gene is deleted by Sanger sequencing.
[0029] Fig.17 The figure shows the results of confirming the phenotype of the DWF5-1 gene in T1 generation transformed tomato plants lacking the DWF5-1 gene by next generation sequencing.
[0030] Fig.18a It is a graph showing the gene editing efficiency and harvested seed amount (upper) and nucleotide sequence (lower) of T1 generation homozygous transformed tomato plants with DWF5-1 gene deletion.
[0031] Fig.18b The figure shows the nucleotide sequence of a T1 generation homozygous transformed tomato plant lacking the DWF5-1 gene.
[0032] Fig.19 is a flow chart showing a sample preparation process for measuring 7-dehydrocholesterol contained in T2 generation transformed tomato plants homozygous (T1) for the DWF5-1 gene deletion.
[0033] Fig. 20 The figure shows the measurement conditions of 7-dehydrocholesterol contained in the body of T2 generation transformed tomato plants homozygous for the DWF5-1 gene deletion (T1) by LC / MS.
[0034] Fig.21 The figure shows the results of measuring 7-dehydrocholesterol contained in wild-type (WT) tomato plants and 7-dehydrocholesterol contained in T2 generation transformed tomato plants of homozygous (T1) for the DWF5-1 gene deletion by LC / MS using commercially available 7-dehydrocholesterol as a standard reagent.
[0035] Fig. 22 The graph shows the results of measuring 7-dehydrocholesterol contained in fruits of T2-generation transformed tomato plants homozygous for the DWF5-1 gene deletion (T1) by LC / MS.
[0036] Fig.23 The graph shows the results of confirming the expression of hygromycin and phosphinothricin (PPT) resistance genes in T2 transformed tomato plants homozygous for the DWF5-1 gene deletion (T1) by RT-PCR.
[0037] Fig.24 The figure shows the results of comparative analysis of the nucleotide sequences of the exon 6 domain of DWF5-1 of T2 generation transformed tomato plants (D100_3-14-29 and D100_7-1-15) that do not express antibiotic resistance genes and the nucleotide sequences of wild-type (WT) tomato plants.
[0038] Fig.25 The figure shows the results of comparative analysis of the amino acid sequences of the exon 6 domain of DWF5-1 of T2 generation transformed tomato plants (D100_3-14-29 and D100_7-1-15) that do not express an antibiotic resistance gene with those of wild-type (WT) tomato plants.
[0039] Fig.26 It is a diagram showing the phenotype of a transformed tomato plant (T2) homozygous for the deletion of the DWF5-1 gene.
[0040] Fig. 27 This is a graph showing the results of confirming the expression level of DWF5-1 or DWF5-2 gene in the roots, stems, leaves and fruits of tomato plants by q-PCR. ****p<0.0001
[0041] Fig.28 The graph shows the results of measuring 7-dehydrocholesterol contained in the roots (cultured roots) of T3 transformed tomato plants homozygous for the DWF5-1 gene deletion (T1) by GC / MS.
[0042] Best Mode for Carrying Out the Invention
[0043] In one aspect of the present invention, there is provided a transformed tomato containing a high concentration of 7-dehydrocholesterol of the following formula 1,
[0044] [Formula 1]
[0045]
[0046] As used herein, the term "tomato" has the scientific name Solanum lycopersicum, and refers to a plant or its fruit belonging to the Solanaceae, Solanales plants. It is an annual plant native to Latin America, 1 to 3 meters tall, with yellow flowers. This fruit is red because it contains lycopene and is used for food. In this specification, the tomato can be a plant body, which can be a plant organ (for example, roots, stems, leaves, petals (flowers), seeds, fruits, etc.), a plant tissue (epidermis, sieve tubes, soft tissue, xylem, vascular tissue), etc. Specifically, it can be a fruit and / or a root. In this case, the tomato plant body can include a cell culture containing a root culture, etc.
[0047] The term "7-dehydrocholesterol" used herein is provitamin D3 converted into vitamin D3. In the present invention, the transformed tomato may contain 0.01 mg to 1.5 mg of 7-dehydrocholesterol per 100 g weight. Specifically, the transformed tomato may contain 0.01 mg, 0.10 mg, 0.20 mg, 0.30 mg, 0.40 mg, 0.50 mg, 0.60 mg, 0.70 mg, 0.80 mg, 0.90 mg, 1.00 mg, 1.10 mg, 1.20 mg, 1.30 mg, 1.40 mg or 1.50 mg of 7-dehydrocholesterol per 100 g weight.
[0048] In the present invention, the transformed tomato can be genetically modified to reduce the expression or activity of the tomato DWF5-1 (DWF5-1) gene or DWF5-1 protein compared to wild-type tomatoes. In this case, the genetic modification can be induced by modification of the nucleic acid sequence.
[0049] The term "DWF5" used herein refers to 7-dehydrocholesterol reductase. This enzyme is also known as delta 5,7-sterol delta 7 reductase. The enzyme has the activity of reducing 5-dehydroepiandrosterol, an intermediate metabolite of the plant sterol metabolic pathway, and converting it into 24-methylene cholesterol.
[0050] It is known that in Arabidopsis thaliana, DWF5 exists in the plant as a single gene, and when the DWF5 gene is lost, plant sterol metabolism decreases sharply, resulting in dwarfism and failure to grow to adulthood. In tomatoes, DWF5 exists in two forms: DWF5-1 and DWF5-2. In this case, DWF5-1 and DWF5-2 may include amino acid sequences SEQ ID NO:2 and SEQ ID NO:4, respectively. It is reported that the DWF5-1 gene plays a role in the plant sterol metabolism pathway, and the DWF5-2 gene plays a role in the cholesterol production pathway by reducing 7-dehydrocholesterol (7-dehydrocholesterol reductase) and converting it into cholesterol. Therefore, when the DWF5-1 gene is lost, it can be expected that plant sterol metabolism is likely to decrease, resulting in abnormal growth. However, since it has been reported that the cholesterol pathway in plants evolved from the plant sterol metabolism pathway, the possibility that DWF5-1 and DWF5-2 have functional homology to each other cannot be completely ruled out. The results of the comparative analysis of the expression patterns of DWF5-1 and DWF5-2 genes in the present invention show that the expression level of DWF5-1 in the leaves, stems, roots, flowers, immature fruits and mature fruits of tomatoes is more than 5-10 times that of the DWF5-2 gene, and the DWF5-2 gene is also expressed at a low expression level in all tissues. Therefore, assuming that DWF5-1 and DWF5-2 have functional homology, it is speculated that the DWF5-1 gene can more effectively increase the 7-dehydrocholesterol content in tomato fruits.
[0051] In the present invention, mutant plants lacking only the DWF5-1 gene produced high levels of provitamin D3 in both immature and mature tomato fruits and root tissues, and their growth and seed production were similar to those of wild-type tomatoes (Figures 18, Fig.26 and Table 13). Therefore, in the present invention, by deleting at least the DWF5-1 gene, tomatoes that produce high concentrations of provitamin D3 in mature fruits were developed, and it was confirmed that the deletion of the DWF5-1 gene alone is an industrially applicable technology that can cultivate and produce fruits similar to the wild type.
[0052] In the present invention, DWF5 may be DWF5-1. Specifically, in the present invention, DWF5 may be DWF5-1 comprising amino acid SEQ ID NO: 2. The DWF5-1 gene may be a genomic DNA, cDNA or RNA comprising a nucleotide sequence encoding DWF5-1. More specifically, in the present invention, the DWF5-1 gene may be a genomic DNA. In the present invention, DWF5, DWF5-1 and SlDWF5-1 may be used interchangeably.
[0053] The term "genomic DNA" used herein refers to chromosomal DNA, which refers to the coded form of genetic information in eukaryotic cells. Eukaryotic genomic DNA (hereinafter referred to as DNA) comprises exons and introns. Exons are the parts of the nucleic acid sequences that comprise protein encoding, and introns are the parts that do not participate in protein synthesis. In order to produce various proteins necessary for organism function, DNA is transcribed into RNA, and now the exons except introns are linked together. Introns comprise information that helps to transcribe, such as promoters that induce transcription initiation, and are used to make pre-mRNA in the transcription process, but can be cut off and not used to make mature mRNA.
[0054] In the present invention, the DWF5-1 gene may include 12 exons and 11 introns. Specifically, DWF5-1 may include exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, exon 9, exon 10, exon 11 or exon 12. In addition, DWF5-1 may include intron 1, intron 2, intron 3, intron 4, intron 5, intron 6, intron 7, intron 8, intron 9, intron 10 or intron 11.
[0055] More specifically, exon 1 to exon 12 of the DWF5-1 gene may respectively contain or consist of nucleic acid sequences SEQ ID NO: 40 to SEQ ID NO: 51. Intron 1 to intron 11 of the DWF5-1 gene may respectively contain or consist of nucleic acid sequences SEQ ID NO: 52 to SEQ ID NO: 62.
[0056] In one embodiment, in the present invention, the DWF5-1 gene may include or consist of the nucleic acid sequence SEQ ID NO:63.
[0057] In the present invention, the DWF5-1 gene may include flanking regions that regulate the transcription of DWF5-1.
[0058] As used herein, the term "flanking region" refers to a DNA sequence extending on both sides of a specific gene, and is a site that is not transcribed into RNA. The DNA region adjacent to the 5' end of the gene is called the 5' flanking region, and the DNA region adjacent to the 3' end of the gene is called the 3' flanking region. The flanking region contains regulatory sequences, which bind to proteins involved in transcription through the above sequences, thereby regulating gene transcription. In particular, in the case of eukaryotic organisms, the 5' flanking region contains enhancers, silencers, promoters, etc., and regulates transcription by binding to proteins such as transcription factors and RNA polymerases.
[0059] In one embodiment of the present invention, the 5' flanking region of the DWF5-1 gene may comprise the nucleic acid sequence of SEQ ID NO: 64. In one embodiment, the 3' flanking region of the DWF5-1 gene may comprise the nucleic acid sequence of SEQ ID NO: 65.
[0060] More specifically, in the present invention, the DWF5-1 gene may be cDNA. In one embodiment, it may comprise or consist of the nucleic acid sequence SEQ ID NO:1.
[0061] As used herein, the term "genetic modification" or "genetically engineered" refers to the act of introducing one or more genetic modifications into a cell or a cell produced therefrom.
[0062] As used herein, the term "reduction in the expression or activity of a gene or protein" means that the expression or activity of a target gene or protein is lower than that of the wild type of the same species in which the target gene or protein can be compared. In addition, "inactivation" means that compared with the wild type target gene or protein, a protein that is not expressed or is inactive even if expressed is produced.
[0063] That is, the reduction or inactivation of the expression or activity of the DWF5-1 gene or protein means that the biological function or effect normally performed by the DWF5-1 gene of the wild-type tomato is completely or partially lost. For example, the protein expressed by the DWF5-1 gene may terminate prematurely or lose its normal function as a protein. Specifically, gene editing can be to knock out the DWF5-1 gene by generating a stop codon in the target region or generating a codon encoding an amino acid different from the wild type. In addition, mutations can also be introduced into non-coding DNA sequences that do not produce proteins, but are not limited to this.
[0064] Specifically, compared to the DWF5-1 gene or protein of wild-type tomatoes, the genetically modified tomatoes can have a DWF5-1 gene or protein reduced by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, or about 100%. The expression or activity of the DWF5-1 gene or DWF5-1 protein can be determined using any method known in the art.
[0065] Genetic modification can be induced by modification of nucleic acid sequences. Specifically, nucleic acid sequences can be modified by replacement (conversion), deletion or insertion to achieve genetic modification. Through the above genetic modification, the DWF5-1 gene of the transformed tomato of the present invention may contain a gene sequence different from the DWF5-1 gene of the wild-type tomato, and the biological function of the above gene may be lost.
[0066] More specifically, the engineering of the DWF5-1 gene can be induced by any modification of the nucleic acid sequence selected from the group consisting of:
[0067] i) deleting the entire or 1 to 50 consecutive nucleotide sequences of the DWF5-1 gene;
[0068] ii) replacing 1 to 50 nucleotides in the DWF5-1 gene with nucleotides different from those in the wild-type DWF5-1 gene;
[0069] iii) inserting 1 to 50 nucleotides each independently selected from A, T, C and G into the DWF5-1 gene; and
[0070] iv) combinations of the above.
[0071] More specifically, genetic modification can be induced by any modification of a nucleic acid sequence selected from the group consisting of:
[0072] i) deleting all or part of the DWF5-1 gene, such as deleting one or more nucleotides of the DWF5-1 gene, such as deleting 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotides;
[0073] ii) replacing one or more nucleotides, such as 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotide in the DWF5-1 gene with a nucleotide different from that of the wild-type DWF5-1 gene;
[0074] iii) inserting one or more nucleotides selected from A, T, C and G, for example 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotide, into any site of the DWF5-1 gene; and
[0075] iv) A combination of i) to iii).
[0076] The portion of the nucleic acid sequence of the DWF5-1 gene that is modified ("target region") can be a region of 1 or more, 3 or more, 5 or more, 7 or more, 10 or more, 12 or more, 15 or more, 17 or more, 20 or more, 25 or more, 27 or more, 30 or more, 33 or more, 37 or more, 40 or more, 43 or more, 47 or more or 50 or more continuous nucleotide sequences in the above-mentioned genes.
[0077] In one embodiment of the present invention, the modification of the nucleic acid sequence of the DWF5-1 gene may be included in the nucleic acid sequence of any one domain selected from the group consisting of exon 6 (SEQ ID NO: 9), exon 7 (SEQ ID NO: 10), exon 9 (SEQ ID NO: 11), exon 10 (SEQ ID NO: 12), exon 11 (SEQ ID NO: 13) and a combination thereof. In one embodiment of the present invention, the modification of the nucleic acid sequence of the DWF5-1 gene may be included in the nucleic acid sequence of the exon 6 domain. Specifically, the nucleotide sequence of SEQ ID NO: 9 containing the nucleic acid sequence of the exon 6 domain of DWF5-1 can be modified by replacement, deletion or insertion in the nucleic acid sequence. More specifically, the modification of the sequence can be induced by replacement, deletion or insertion in the nucleotide sequence of SEQ ID NO: 9 containing the nucleic acid sequence of the exon 6 domain of the DWF5-1 gene to reduce the expression or activity of the DWF5-1 gene or the DWF5-1 protein, or to cause the presence of a stop codon.
[0078] The transformed tomato of the present invention can be further genetically modified to reduce the expression or activity of the CPD gene or CPD protein. The genetic modification is the same as described above.
[0079] As used herein, the term "CPD (constitutive photomorphogen DWAF)" is an enzyme of the CP90A family of cytochrome P450 monooxygenases, also known as DWF3. In the biosynthesis of brassinolide, it acts on the C6 oxidation pathway to convert cathasterone to teasterone and 6-deoxy-brassinosterone to 6-deoxy-teasterone. In the present invention, the role of the above enzyme is to reduce 7-dehydrocampesterol to 7-dehydrocampestanol.
[0080] In this case, the CPD may comprise the amino acid sequence of SEQ ID NO: 6. Furthermore, the nucleic acid encoding it may comprise the nucleotide sequence of SEQ ID NO:5.
[0081] In the present invention, the reduction or inactivation of the expression or activity of the CPD gene or CPD protein means that the biological function or effect normally performed by the CPD gene of the wild-type tomato is completely or partially lost. At this time, the reduction or inactivation of the expression or activity of the gene or protein is the same as described above. For example, the protein expressed by the CPD gene may terminate prematurely or lose its normal function as a protein. Specifically, gene editing can be to knock out the CPD gene by generating a stop codon in the target region or generating a codon encoding an amino acid different from the wild type. In addition, mutations can also be introduced into non-coding DNA sequences that do not produce proteins, but are not limited to this.
[0082] Specifically, the genetically modified tomato may have a CPD gene or protein reduced by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, or about 100% compared to the CPD gene or protein of the wild-type tomato. The expression or activity of the CPD gene or CPD protein may be determined using any method known in the art.
[0083] Genetic modification can be induced by modification of nucleic acid sequences. Specifically, nucleic acid sequences can be modified by replacement, deletion or insertion to achieve genetic modification. Through the above genetic modification, the CPD gene of the transformed tomato of the present invention may contain a gene sequence different from the CPD gene of the wild-type tomato, and the biological function of the above gene may be lost.
[0084] More specifically, the engineering of the CPD gene can be induced by any modification of the nucleic acid sequence selected from the group consisting of:
[0085] i) deleting the entire or 1 to 50 consecutive nucleotide sequences of the CPD gene;
[0086] ii) replacing 1 to 50 nucleotides in the CPD gene with nucleotides different from those in the wild-type CPD gene;
[0087] iii) inserting 1 to 50 nucleotides each independently selected from A, T, C and G into the CPD gene; and
[0088] iv) combinations of the above.
[0089] More specifically, genetic modification can be induced by any modification of a nucleic acid sequence selected from the group consisting of:
[0090] i) deleting all or part of a CPD gene, such as deleting one or more nucleotides of a CPD gene, such as deleting 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotides;
[0091] ii) replacing one or more nucleotides, such as 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotide in the CPD gene with a nucleotide different from that of the wild-type CPD gene;
[0092] iii) inserting one or more nucleotides selected from A, T, C and G, for example 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotide, into any site of the CPD gene; and
[0093] iv) A combination of i) to iii).
[0094] The portion of the nucleic acid sequence of the CPD gene that is modified ("target region") can be a region of 1 or more, 3 or more, 5 or more, 7 or more, 10 or more, 12 or more, 15 or more, 17 or more, 20 or more, 25 or more, 27 or more, 30 or more, 33 or more, 37 or more, 40 or more, 43 or more, 47 or more or 50 or more continuous nucleotide sequences in the above-mentioned genes.
[0095] In one embodiment of the present invention, the modification of the nucleic acid sequence of the CPD gene may be included in the nucleic acid sequence of any one domain selected from the group consisting of exon 7 (SEQ ID NO: 14), exon 8 (SEQ ID NO: 15) and a combination thereof. In one embodiment of the present invention, the modification of the nucleic acid sequence of the CPD gene may be a modification of the nucleic acid sequence of the exon 8 domain. Specifically, the nucleotide sequence of SEQ ID NO: 15 of the nucleic acid sequence of the exon 8 domain of the CPD gene may be modified by replacement, deletion or insertion in the nucleic acid sequence. More specifically, the modification of the sequence may be induced by replacement, deletion or insertion in the nucleotide sequence of SEQ ID NO: 15 of the nucleic acid sequence of the exon 8 domain of the CDP gene to reduce the activity of the CDP or cause the presence of a stop codon.
[0096] The transformed tomato containing DWF5-1 and CPD gene mutations of the present invention can be further genetically modified to reduce the expression or activity of the SMT1 gene or SMT1 protein. The genetic modification is the same as described above.
[0097] As used herein, the term "SMT1 (sterol methyltransferase 1)" is an enzyme that adds a methyl group to a steroid side chain. Specifically, the role of SMT1 is to convert 5-dehydroepisterol to 7-dehydrocampesterol.
[0098] In this case, SMT1 may comprise the amino acid sequence of SEQ ID NO: 8. Furthermore, the nucleic acid encoding it may comprise the nucleotide sequence of SEQ ID NO:7.
[0099] In the present invention, the reduction or inactivation of the expression or activity of the SMT1 gene or SMT1 protein means that the biological function or effect normally performed by the SMT1 gene of the wild-type tomato is completely or partially lost. At this time, the reduction or inactivation of the expression or activity of the gene or protein is the same as described above. For example, the protein expressed by the SMT1 gene may terminate prematurely or lose its normal function as a protein. Specifically, gene editing can be to knock out the SMT1 gene by generating a stop codon in the target region or generating a codon encoding an amino acid different from the wild type. In addition, mutations can also be introduced into non-coding DNA sequences that do not produce proteins, but are not limited to this.
[0100] Specifically, the genetically modified tomato may have a SMT1 gene or SMT1 protein reduced by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, or about 100% compared to the SMT1 gene or SMT1 protein of the wild-type tomato. The expression or activity of the SMT1 gene or SMT1 protein may be determined using any method known in the art.
[0101] Genetic modification can be induced by modification of nucleic acid sequences. Specifically, nucleic acid sequences can be modified by replacement, deletion or insertion to achieve genetic modification. Through the above genetic modification, the SMT1 gene of the transformed tomato of the present invention may contain a gene sequence different from the SMT1 gene of the wild-type tomato, and the biological function of the above gene may be lost.
[0102] More specifically, the engineering of the SMT1 gene can be induced by any modification of the nucleic acid sequence selected from the group consisting of:
[0103] i) deleting all or 1 to 50 consecutive nucleotide sequence regions of the SMT1 gene;
[0104] ii) replacing 1 to 50 nucleotides in the SMT1 gene with nucleotides different from those in the wild-type SMT1 gene;
[0105] iii) inserting 1 to 50 nucleotides each independently selected from A, T, C and G into the SMT1 gene; and
[0106] iv) combinations of the above.
[0107] More specifically, genetic modification can be induced by any modification of a nucleic acid sequence selected from the group consisting of:
[0108] i) deleting all or part of the SMT1 gene, such as deleting one or more nucleotides of the SMT1 gene, such as deleting 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotides;
[0109] ii) replacing one or more nucleotides, such as 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotide in the SMT1 gene with a nucleotide different from that of the wild-type SMT1 gene;
[0110] iii) inserting one or more nucleotides selected from A, T, C and G, for example 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3 or 1 nucleotide, into any site of the SMT1 gene; and
[0111] iv) A combination of i) to iii).
[0112] The portion of the nucleic acid sequence of the SMT1 gene that is modified ("target region") can be a region of 1 or more, 3 or more, 5 or more, 7 or more, 10 or more, 12 or more, 15 or more, 17 or more, 20 or more, 25 or more, 27 or more, 30 or more, 33 or more, 37 or more, 40 or more, 43 or more, 47 or more or 50 or more continuous nucleotide sequences in the above-mentioned genes.
[0113] In one embodiment of the present invention, the modification of the nucleic acid sequence of the SMT1 gene may be included in the nucleic acid sequence of any one domain selected from the group consisting of exon 7 (SEQ ID NO: 16), exon 9 (SEQ ID NO: 17), exon 11 (SEQ ID NO: 18), exon 12 (SEQ ID NO: 19) and a combination thereof. In one embodiment of the present invention, the mutation of the SMT1 gene may include the modification of the nucleic acid sequence of the exon 7 and exon 9 domains. Specifically, the mutation of the SMT1 gene may be a modification of the nucleotide sequence of SEQ ID NO: 16 and SEQ ID NO: 17 comprising the nucleic acid sequence of the exon 7 and exon 9 domains by substitution, deletion or insertion. More specifically, the modification of the sequence may be induced by substitution, deletion or insertion in the nucleotide sequence of SEQ ID NO: 16 and SEQ ID NO: 17 comprising the nucleic acid sequence of the exon 7 and exon 9 domains of the SMT1 gene to reduce the activity of SMT1 or cause the presence of a stop codon.
[0114] The transformed tomato may be homozygous. That is, the modification of the nucleic acid sequence may be included in two genes encoding DWF5-1. In one embodiment, the modification of the nucleic acid sequence may be included in two genes encoding any one domain selected from the group consisting of exon 6, exon 7, exon 9, exon 10, exon 11 and combinations thereof of the DWF5-1 gene. In one embodiment of the present invention, the transformed tomato may have a modified sequence in two genes encoding the exon 6 domain of the DWF5-1 gene, which is different from the nucleic acid sequence of the wild-type DWF5-1 gene.
[0115] In the transformed tomato, the modification of the nucleic acid sequence may be included in two genes encoding DWF5-1, CPD and SMT1. In this case, the transformed tomato may have a modified sequence in two genes encoding any domain selected from the group consisting of exon 7, exon 8 and a combination thereof of the CPD gene, and the modified sequence is different from the nucleic acid sequence of the wild-type CPD gene. In addition, the modification of the nucleic acid sequence may be included in two genes encoding any domain selected from the group consisting of exon 7, exon 9, exon 11, exon 12 and a combination thereof of the SMT1 gene. In this case, the modification of the nucleic acid sequence is the same as described above.
[0116] In one embodiment of the present invention, in the transformed tomato, the modification of the nucleic acid sequence may be included in two genes encoding the exon 6 domain of DWF5-1, the exon 7 domain of CDP, and the exon 7 and exon 9 domains of SMT1, respectively.
[0117] When the transformed tomato of the present invention is homozygous, and the expression or activity of the DWF5-1 gene or protein is reduced or inactivated, the tomato can form seeds. When the transformed tomato is homozygous, and the expression or activity of the DWF5-1, CPD and SMT1 genes or proteins is reduced or inactivated, the tomato may not bear fruit and may not form seeds.
[0118] In another aspect of the present invention, a vector is provided, which comprises one or more sgRNAs complementary to the nucleotide sequence of the DWF5-1 gene and a nucleotide sequence encoding a CRISPR-associated protein. Here, DWF5-1 is the same as described above. In addition, the DWF5-1 gene can be genomic DNA, cDNA or RNA.
[0119] The term "guide RNA (gRNA)" as used herein refers to a polynucleotide that recognizes a target nucleic acid in a cell and cuts, inserts, or connects the target nucleic acid by genome editing. The gRNA may include a sequence complementary to a target sequence in the target nucleic acid. The gRNA may be a polynucleotide complementary to a nucleotide sequence of 2 to 24 consecutive nucleotides (hereinafter referred to as 'nt') in the 5' or 3' direction of the PAM in the target nucleic acid. The length of the gRNA may be 17nt, 18nt, 19nt, 20nt, 21nt, 22nt, 23nt, or 24nt.
[0120] gRNA can be a single-stranded guide RNA (sgRNA). sgRNA can include CRISPR RNA (crRNA) for a target nucleic acid sequence and / or a trans-activating crRNA (tracrRNA) that forms a complex with CRISPR-related proteins. sgRNA can include a portion (also referred to as a spacer, a target DNA recognition sequence, a base pairing region, etc.) having a nucleotide sequence (targeting sequence) complementary to the target nucleic acid sequence (target region) in the target gene and a hairpin structure for binding to CRISPR-related proteins. More specifically, it can include a portion of a nucleotide sequence (targeting sequence) complementary to the target nucleic acid sequence in the target gene, a hairpin structure for binding to CRISPR-related proteins, and a terminator sequence. The above structure can exist sequentially from 5' to 3', but is not limited thereto. Any type of sgRNA can be used, as long as the sgRNA includes the main regions of crRNA and tracrRNA and a nucleotide sequence complementary to the target gene.
[0121] In the present invention, sgRNA can complementarily bind to the nucleic acid sequence of the genomic DNA of DWF5-1. Specifically, sgRNA can complementarily bind to SEQ ID NO:63. More specifically, sgRNA can complementarily bind to the nucleic acid sequence of one or more domains selected from the group consisting of exon 1 to exon 12, intron 1 to intron 11, 5' flanking region and 3' flanking region of the DWF5-1 gene. More specifically, sgRNA can complementarily bind to the nucleic acid sequence of one or more domains selected from the group consisting of SEQ ID NO:40 to SEQ ID NO:62, SEQID NO:64 and SEQ ID NO:65.
[0122] In the present invention, the sgRNA can be complementary to the nucleic acid sequence of the cDNA of DWF5-1. Specifically, the sgRNA can be complementary to the nucleic acid sequence of SEQ ID NO: 1.
[0123] In one embodiment of the present invention, the sgRNA may be complementary to the nucleic acid sequence of any domain selected from the group consisting of exon 6, exon 7, exon 9, exon 10 and exon 11 of the DWF5-1 gene. In one embodiment, the sgRNA that binds to the nucleic acid sequence of the exon 6 domain of the DWF5-1 gene may include the nucleotide sequence SEQ ID NO: 20 or SEQ ID NO: 21. In one embodiment, the sgRNA that binds to the nucleic acid sequence of the exon 7 domain may include the nucleotide sequence SEQ ID NO: 22. In one embodiment, the sgRNA that binds to the nucleic acid sequence of the exon 9 domain may include the nucleotide sequence SEQ ID NO: 23 or SEQ ID NO: 24. In one embodiment, the sgRNA that binds to the exon 10 domain may include the nucleotide sequence SEQ ID NO: 25. In one embodiment, the sgRNA that binds to the nucleic acid sequence of the exon 11 domain may include the nucleotide sequence SEQ ID NO: 26. Preferably, in one embodiment of the present invention, the sgRNA may include or consist of the nucleotide sequences SEQ ID NO: 20 and SEQ ID NO: 21 that complementarily bind to the nucleic acid sequence of the exon 6 domain.
[0124] In the present invention, the vector may further comprise an sgRNA that is complementary to the nucleotide sequence of the CPD gene. The sgRNA that is complementary to the CPD gene may be complementary to the nucleotide sequence of the exon 7 or exon 8 domain of the CPD gene. The sgRNA that binds to the exon 7 domain of the CPD gene may comprise the nucleotide sequence SEQ ID NO:27. The sgRNA that binds to the exon 8 domain of the CPD gene may comprise the nucleotide sequence SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, or SEQ ID NO:31. In one embodiment of the present invention, the sgRNA may comprise the nucleotide sequences SEQ ID NO:28 and SEQ ID NO:29 that are complementary to the nucleotide sequence of the exon 8 domain.
[0125] In the present invention, the vector comprising sgRNAs that complementarily bind to the nucleotide sequences of the DWF5 gene and the CPD gene may also comprise sgRNAs that complementarily bind to the nucleotide sequences of the SMT1 gene. In this case, the sgRNAs that complementarily bind to the nucleotide sequences of the SMT1 gene may complementarily bind to the nucleotide sequences of one or more domains selected from the group consisting of exon 7, exon 9, exon 11, and exon 12 of the SMT1 gene. The sgRNAs that bind to the exon 7 domain of the SMT1 gene may comprise the nucleotide sequence SEQ ID NO: 32. The sgRNAs that bind to the exon 9 domain of the SMT1 gene may comprise the nucleotide sequence SEQ ID NO: 33. The sgRNAs that bind to the exon 11 domain of the SMT1 gene may comprise the nucleotide sequence SEQID NO: 34. The sgRNAs that bind to the exon 12 domain of the SMT1 gene may comprise the nucleotide sequence SEQ ID NO: 35. In one embodiment of the present invention, the sgRNA may include nucleotide sequences SEQ ID NO: 32 and SEQ ID NO: 33 that complementarily bind to the nucleotide sequences of exon 7 and exon 9. In this case, the sgRNAs that complementarily bind to the nucleotide sequences of the DWF5 gene and the CPD gene are the same as described above.
[0126] The term "CRISPR (clustered regularly interspaced palindromic repeats)-associated protein" (CRISPR-associated protein) used herein refers to an enzyme that can recognize and cut nucleic acids when nucleic acids such as DNA or RNA have double strands or single strands (dsDNA / RNA and ssDNA / RNA). Specifically, it can recognize double-stranded or single-stranded nucleic acids bound to sgRNA and cut them. The CRISPR-associated protein includes CRISPR-associated proteins and mutants having their functions.
[0127] CRISPR-associated proteins can be derived from: Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus sp., Staphylococcus aureus, Nocardiopsis dassonvillei, Streptomyces pristinae spiralis, Streptomyces viridochromogenes, Streptosporangium roseum, Alicyclobacillus acidocaldarius, Bacillus pseudomycoides, Bacillus selenitireducens, Exiguobacterium sibiricum, Lactobacillus delbrueckii, delbrueckii), Lactobacillus salivarius, Microscilla marina, Burkholderialesbacterium, Polaromonas naphthalenivorans, Polaromonas sp., Crocosphaera watsonii, Cyanothece sp., Microcystis aeruginosa, Pseudomonas aeruginosa, Synechococcus sp.), Acetohalobium arabaticum, Ammonifex degensii, Caldicelulosiruptor becscii, Candidatus Desulforudis, Clostridium botulinum, Clostridium difficile, Finegoldia magna, Natranaerobius thermophilus, Pelotomaculumthermopropionicum, Acidithiobacillus caldus, Acidithiobacillus ferrooxidans, Allochromatium vinosum, Marinobacter sp., Nitrosococcus halophilus), Nitrosococcus watsoni, Pseudoalteromonas haloplanktis, Ktedonobacter racemifer, Methanohalobium evestigatum, Anabaena variabilis, Nodularia spumigena, Nostoc sp., Arthrospira maxima, Arthrospira platensis, Arthrospira sp., Lyngbya sp., Microcoleus chthonoplastes, Oscillatoria sp., Petrotogamobilis, Thermosipho africanus, Acaryochlorismarina, Leptotrichia shahii, Prevotella or Francisella novicida.
[0128] In the present invention, the CRISPR-associated protein can be any one selected from the group consisting of: Cas9, Cpf1, c2c1, C2c2, Cas13, c2c3, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a, Cas8a1, Cas8a2, Cas8b, Cas8c, Csn1, Csx12, Cas10, Cas10d, Cas10, Cas10d, CasF, CasG, CasH, Csyl, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), Cse4 (CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4 and Cul966. Specifically, the CRISPR-associated protein can be Cas9.
[0129] The Cas9 protein can form a complex with the guide sgRNA, acting as a ribonucleoprotein (RNP). Here, "ribonucleoprotein (RNP)" is a complex of RNA and protein, which can be a Cas9-sgRNA complex in the present invention.
[0130] As used herein, the term "vector" is capable of being introduced into a host cell and then recombined and inserted into the genome of the host cell. Alternatively, a vector is understood to be a nucleic acid delivery vehicle comprising a polynucleotide sequence that can replicate autonomously as an episome. Such vectors include linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors, minichromosomes, and the like. Examples of viral vectors include, but are not limited to, retroviruses, adenoviruses, and adeno-associated viruses.
[0131] In one embodiment of the present invention, the vector may comprise any one of the nucleotide sequences SEQ ID NO: 36 to SEQ ID NO: 38. In addition, in the present invention, the vector has about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence homology with any one of SEQ ID NO: 36 to SEQ ID NO: 38. In addition, the vector may be partially or completely codon-optimized for expression in a target organism or cell.
[0132] The vector can be operably connected to a suitable promoter so that the polynucleotide can be expressed in a host cell. When the vector of the present invention is applied to a plant cell, the promoter of the present invention can include a promoter for introducing a gene into a plant body. The example of a promoter can include but is not limited to SP6 promoter, T7 promoter, T3 promoter, PM promoter, corn ubiquitin promoter (Ubi), cauliflower mosaic virus (CaMV) 35S promoter, nopaline synthase (nos) promoter, figwort mosaic virus 35S promoter, sugarcane bacilliform virus promoter, Commelina yellow mottle virus promoter, ribulose-1,5-bisphosphate carboxylase small subunit (ssRUBISCO) light-inducible promoter, rice cytoplasmic triosephosphate isomerase (TPI) promoter, Arabidopsis adenine phosphoribosyltransferase (APRT) promoter and octopine synthase promoter.
[0133] Specifically, the vector may be a plasmid DNA, a phage DNA, etc. In addition, the vector may be a commercially developed plasmid (pUC18, pBAD, pIDTSAMRT-AMP, etc.), a plasmid derived from Escherichia coli (pYG601BR322, pBR325, pUC118, pUC119, etc.), a plasmid derived from Bacillus subtilis (pUB110, pTP5, etc.), a plasmid derived from yeast (YEp13, YEp24, YCp50, etc.), a phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, λgt10, λgt11, λZAP, etc.), an animal virus vector (retrovirus, adenovirus, vaccinia virus, etc.), an insect virus vector (baculovirus, etc.), etc. Since the expression amount and modification of the protein of the vector differ depending on the host cell, it is preferred to select and use the host cell most suitable for the purpose.
[0134] In the present invention, carriers can include selective markers. Selective markers are nucleotide sequences with characteristics that can be selected by conventional chemical methods, including all genes that can distinguish transformed cells from non-transformed cells. The example of mark can include but is not limited to herbicide resistance genes, such as glyphosate, phosphine ammonium glufosinate or phosphine glufosinate, and antibiotic resistance genes, such as kanamycin, G418, bleomycin, hygromycin and chloramphenicol. In one embodiment of the invention, the selective marker can be hygromycin and / or phosphine glufosinate.
[0135] In another aspect of the present invention, a method for producing transformed tomatoes containing a high concentration of 7-dehydrocholesterol is provided, comprising introducing a vector comprising a gene encoding an sgRNA and a gene encoding a CRISPR-associated protein into tomatoes using Agrobacterium.
[0136] Transformed plants can be constructed by plant transformation methods known in the art. Those of ordinary skill in the art can select and implement known transformation methods suitable for specific plants based on the characteristics of the selected host plant. Specifically, transformation methods using Agrobacterium can be used as plant transformation methods.
[0137] The "transformation method using Agrobacterium" is a method of transferring foreign genes into plant cells using Agrobacterium, a Gram-negative soil bacterium that causes tumors to form in the roots and stems of plants. This is a method that utilizes the phenomenon that the T-DNA (transfer DNA) of the tumor-inducing plasmid (Ti plasmid) found in Agrobacterium (such as Agrobacterium tumefaciens and Agrobacterium rhizogenes) is inserted into the plant genome.
[0138] In one embodiment of the present invention, when the nucleic acid sequence modification is included in the exon 6 domain of the DWF5-1 gene, the homozygous tomato (T1) can produce seeds (Figure 18). In addition, the homozygous T2 generation tomato with the modified nucleic acid sequence in the exon 6 domain of the DWF5-1 gene can grow normally and produce seeds (Figure 18). Fig.26 ), and 7-dehydrocholesterol accumulated at high concentrations in fruits and roots (Table 14, Fig.21 and Fig. 22 ). However, when the nucleic acid sequences in the exon 6 domain of the DWF5-1 gene and the exon 8 domain of the CPD gene of the transformed tomato included modifications, the tomato could not grow into a complete plant. In addition, when the transformed tomato was homozygous for the nucleic acid sequences in the exon 6 domain of the DWF5-1 gene, the exon 8 domain of the CPD gene, and the exon 7 and exon 9 domains of the SMT1 gene, no fruit was produced. DETAILED DESCRIPTION
[0139] The present invention is described in more detail by the following examples. However, the following examples are only used to illustrate the present invention, and the scope of the present invention is not limited to these examples.
[0140] Example 1. Construction of Cas9-sgRNA vector for gene editing of DWF5, CPD and SMT1
[0141] DWF5-1 (hereinafter referred to as “DWF5”) for gene editing was designed and selected through the Cas-Designer website (http: / / www.rgenome.net / cas-dessdaigner / ). Figure 1 )、CPD( Figure 2 ) and SMT1( Figure 3) sgRNA. Select the name or sequence of the target gene, the animal or plant species, and then select the Cas9 to be used. Design the sgRNA based on the desired exon site in the gene, the GC content of the sgRNA, the off-target results at the mismatch, etc. The PAM sequence of Cas9 is NGG-3', and tomato (S. lycopersicum) is selected as the plant ( Figures 1 to 3 In addition, sgRNAs were screened to confirm gene editing efficiency (Table 2 and Figures 1 to 3 ).
[0142] Specifically, RGEN (RNA-guided endonuclease) analysis was used to perform the targeting suitability of sgRNA. The DNA template was purified from the above-amplified PCR product (PCR product) using a PCR purification kit, and then the amount of DNA template was measured, and RGEN was performed according to the combination shown in Table 1. After incubation at 37°C for 1 hour, 3 μL of 6xDNA-Purple dye was added to each, frozen, and then loaded onto a 2.5% gel. Gene editing efficiency was analyzed by analyzing the degree of uncut bands in the DNA template.
[0143] [Table 1]
[0144]
[0145] The results showed that among the constructed sgRNAs targeting the DWF5 gene, all sgRNAs except D5-4 and D5-6 were confirmed to be able to target the DWF5 gene ( Figure 4 All CPD sgRNAs except C1 target the CPD gene ( Figure 5 ), and all constructed SMT1 sgRNAs targeted the CPD gene ( Figure 6 ).
[0146] [Table 2]
[0147]
[0148]
[0149] According to the results of sgRNA screening, Cas9-sgRNA vectors containing sgRNAs constructed to target DWF5, CPD or SMT1 were finally constructed. The pNGPJ0014 vector (SEQ ID NO: 39) was constructed based on the pCAMBIA1300 plasmid with kanamycin and hygromycin resistance genes.
[0150] The pNGPJ0014 vector has an antibiotic cassette for kanamycin and hygromycin antibiotic selection, and a polycistronic tRNA-gRNA cassette synthesized with Cas9. Cas9 was constructed to be expressed from the Arabidopsis thaliana ubiquitin 10 (Ubi 10) promoter, and the tRNA-gRNA was constructed to be expressed from the Arabidopsis thaliana ubiquitin 6 promoter.
[0151] In order to deliver the Cas9 protein into the cell nucleus, the SV40 (PKKKRKV) nuclear localization signal sequence was added to the N-terminus of the Cas9 open reading frame, and the Bipartite (KEPAATKKAGQAKKKK) nuclear localization signal sequence was added to the C-terminus. At this time, the Cas9-sgRNA vector was constructed to target one to three types of genes. In addition, it was constructed to load two types of sgRNAs for each target. The Cas-sgRNA vector containing the nucleotide sequences of D5-1 sgRNA (SEQ ID NO: 20) and D5-2 sgRNA (SEQ ID NO: 21) targeting the DWF5 gene was named "D100" (SEQ ID NO: 36) ( Figure 7 ).
[0152] The Cas9-sgRNA vector targeting the CPD and DWF5 genes was named "D120" (SEQ ID NO: 37). At this time, the CPD sgRNA contained the nucleotide sequences of C2 (SEQ ID NO: 28) and C3 (SEQ ID NO: 29), and the DWF5 sgRNA contained the nucleotide sequences of D5-1 (SEQ ID NO: 20) and D5-2 (SEQ ID NO: 21) ( Figure 8 ).
[0153] The Cas9-sgRNA vector targeting the SMT1, CPD, and DWF5 genes was named "D121" (SEQ ID NO: 38). At this time, the SMT1 sgRNA contained the nucleotide sequences of S1 (SEQ ID NO: 32) and S2 (SEQ ID NO: 33), the CPD sgRNA contained the nucleotide sequences of C2 (SEQ ID NO: 28) and C3 (SEQ ID NO: 29), and the DWF5 sgRNA contained the nucleotide sequences of D5-1 (SEQ ID NO: 20) and D5-2 (SEQ ID NO: 21) ( Fig. 9 ).
[0154] Example 2. Transformation of tomato by DWF5, CPD and SMT1 gene editing
[0155] Tomato transformation according to Fig.10The preparation and use of the culture medium and hormones used in each step were the same as those described in Tables 3 to 8.
[0156] [Table 3]
[0157]
[0158]
[0159] [Table 4]
[0160]
[0161] [Table 5]
[0162]
[0163] [Table 6]
[0164]
[0165] [Table 7]
[0166]
[0167] [Table 8]
[0168]
[0169] [Table 9]
[0170]
[0171]
[0172] Specifically, tomato seeds were sterilized with 70% ethanol for 5 seconds and 2% bleach for 20 minutes. The sterilized seeds were washed 4 to 5 times with sterile water, and then placed on sterile filter paper to remove moisture. The sterilized tomato seeds were transferred to the sowing medium TMS (Table 3), cultured under dark culture conditions at 25°C for 3 days, and then transferred to light culture conditions for culture. After sowing, when the cotyledons grew 1cm to 1.5cm (9 to 12 days), the top of the tomato hypocotyl was cut to 0.7cm to 1.0cm, and about 18 to 20 (4, 5, 5 and 4, or 5, 5, 5 and 5, a total of 18 to 20) were planted on TPC medium plates (Table 4) and cultured for 1 day under light culture conditions (16L / 8D).
[0173] Agrobacterium (GV3101 strain, DSMZ, CAT. No. DSM12364) was cultured in 50 mL bacterial culture medium (YEP) containing 100 mM AS (acetosyringone) and 50 mg / L rifampicin, 50 mg / L kanamycin (Km) at 28°C under dark culture conditions for 1 to 2 days to obtain an OD600 value of 0.8 to 1.2.
[0174] The cultured bacteria were centrifuged at 4°C, 6,000 rpm for 15 minutes to remove the supernatant, and the pellet was resuspended in an equal amount of tomato co-cultivation (TCC) medium (Table 5) and diluted to an OD value of 0.5.
[0175] 40 mL of bacterial culture solution (OD600 value 0.5) prepared as described above and the plant body pretreated under light culture conditions were placed in a 50 mL test tube (based on sowing 200 seeds) and cultured at room temperature of 25°C for 20 to 30 minutes. The co-cultured explants were transferred to sterile filter paper, dried as much as possible to remove moisture, and then about 18 to 20 (4, 5, 5 and 4, or 5, 5, 5 and 5, a total of 18 to 20) were inoculated on TCC medium plates (Table 5) and cultured at 25°C for 2 days under light culture conditions (16L / 8D). After 2 days of co-culture, the explants were transferred to bud selection medium (TSI, Table 7) and cultured in a plant incubator at 25°C under light conditions (16L / 8D). At this point, while the Agrobacterium was growing, 300 mg / L carbenicillin was added to the co-cultivation liquid medium, washed, and then dried on filter paper before replanting on the medium.
[0176] 3 to 4 weeks after planting, callus differentiates from the cut part. When the differentiated callus induces budding and grows to more than 1 cm, it is transferred to the rooting medium (Table 9) to induce roots. At this time, the callus is removed as much as possible, and rooting is induced by transplanting the bud part. After the root is completely rooted, the root is rinsed with tap water to remove the Agrobacterium remaining on the root, and transplanted into the soil. While maintaining the culture room environment, it is adapted to the external environment (humidity changes and non-sterile conditions) for cultivation.
[0177] Fig.11 Shown are the changes in callus along with the stages of plant differentiation.
[0178] The results are as follows Figure 12 to Figure 14 As shown, use D100( Fig.12 ) or D121( Fig.14 ) transformed tomato buds grew normally into plants, but tomato explants transformed with D120 did not grow normally ( Fig.13 ).
[0179] Example 3. Sequencing of tomato plants generated by DWF5, CPD and SMT1 gene editing
[0180] To confirm the transformation of the tomato plants obtained in Example 2, the T7E1 assay was performed on tomato subjects transformed with D100 or D121 ( Fig.15 ) and Sanger sequencing ( Fig.16 and Table 12).
[0181] Specifically, in the T7E1 assay, the target region is first amplified by PCR, and then the amplified PCR product is purified using a PCR purification kit. Using the purified PCR product as a DNA template, heteroduplex formation is performed according to the conditions of Table 11 and the combination shown in Table 10. Then add 1 μL of T7 endonuclease I (T7E1) and react at 37°C for 30 minutes. Finally, treat with 1 μL of proteinase K and react at 37°C for 5 minutes to inactivate the T7E1 enzyme activity. The gene editing efficiency is evaluated by the fragment concentration in the PCR product.
[0182] [Table 10]
[0183] PCR product (250ng) 5μL 10xNEB Buffer 2 2μL Nuclease-free water Make up to 14 μL
[0184] [Table 11]
[0185]
[0186]
[0187] Sanger sequencing was performed as follows. The sgRNA target region was amplified from genomic DNA extracts in a 20 μL reaction volume using Q5 high-fidelity DNA polymerase (New England Biolabs). Subsequently, the PCR products were cloned into a TA vector using an All in one Cloning Kit (Biofact, South Korea), and 15 to 20 clones successfully cloned for each sample were sequenced individually. As a result, 14 tomato homozygotes with DWF5 gene deletion generated by D100 transformation were identified ( Fig.15 and 16 In addition, a tomato homozygous for the deletion of DWF5, CPD and SMT1 genes was identified by D121 transformation ( Fig.15 and Table 12). Taking D121 transformed plants as an example, the gene deletion caused plant hormone imbalance, resulting in the inability to form fruits.
[0188] [Table 12]
[0189]
[0190]
[0191] Example 4. Obtaining tomato seeds produced by DWF5 gene editing and tomato gene phenotype analysis
[0192] Seeds (DWF5 homozygotes) obtained from 7 tomatoes in which the DWF5 gene was deleted by gene scissors (T0 generation) were sown and subjected to next generation sequencing (NGS) to determine whether tomatoes in which the DWF5 gene was deleted in the next generation (T1 generation) were obtained.
[0193] The results confirmed that 12 of the 23 seeds (T1) obtained from 7 T0 subjects were homozygous ( Fig.17 ). In addition, from the above 12 seeds, 6 seeds with a gene editing efficiency (indel efficiency) of 100% were selected, and the occurrence of seeds (T2) and the amount of seeds obtained were confirmed. As a result, 5 of the 6 objects produced seeds (Figure 18 and Table 13). In addition, it was observed that the phenotypes of fruits, leaves, and stems of tomatoes with DWF5 gene deletion were not significantly different from those of wild-type tomatoes. Here, wild-type tomatoes (wild type, WT) are the control group.
[0194] [Table 13]
[0195]
[0196]
[0197] Example 5. Phenotypic analysis of T2 generation
[0198] Example 5.1. Analysis of Vitamin D3 Precursors
[0199] The seeds (T2) obtained in Example 4 were sown, and the content of provitamin D3 contained in the T2 generation tomatoes was determined by LC / MS. At this time, wild-type tomatoes (WT), T2 generation of #3-14 strain (D100-3-14) (4 subjects) and T2 generation of #7-1 strain (D100-7-1) (11 subjects) were used as samples. 7-dehydrocholesterol, a precursor of animal provitamin D3 (provitamin D3, sigma, Cat30800, Lot. BCBS6021), was used as a standard reagent. In addition, wild-type (WT) tomatoes were used as samples as a control group.
[0200] Specifically, a certain amount of each sample was weighed, and 30 mL of ethanol and 1 mL of 10% ethanolic pyrogallo were added. Then 3 mL of 90% potassium hydroxide (KOH) was added, and the mixture was reacted in an 80°C water bath for 30 minutes, and vortexed every 10 minutes. After the reaction was completed, the mixture was cooled to room temperature, and then 30 mL of distilled water and 30 mL of n-hexane were added and shaken for 1 hour. Then, the supernatant was transferred to a separatory funnel, and 30 mL of n-hexane was added to the water layer and vortexed. The supernatant was transferred to a separatory funnel again, and 100 mL of distilled water was added to the hexane layer to wash with water. The water washing process was repeated twice. Subsequently, the hexane layer was dehydrated with anhydrous sodium sulfate, then concentrated, dissolved in 5 mL of methanol (MeOH), and filtered through a polytetrafluoroethylene (PTFE) filter to prepare a test solution ( Fig.19 ).
[0201] exist Fig. 20 Under the conditions of , 7-dehydrocholesterol contained in the test solution prepared as described above was measured by LC / MS.
[0202] As a result, 7-dehydrocholesterol was not detected in the fruit part of WT tomatoes, but was detected in 4 subjects in the #3-14 line and 11 subjects in the #7-1 line (a total of 15 subjects) in the T2 generation (Table 14, Fig.21 and Fig. 22 ).
[0203] [Table 14]
[0204]
[0205]
[0206] Example 5.2. Analysis of vitamin D3 precursors in tomato roots
[0207] The seeds (T2) obtained in Example 4 were sterilized with 70% ethanol for 5 seconds and 2% bleach for 20 minutes. The sterilized seeds were washed 4 to 5 times with sterile water, and then placed on sterile filter paper to remove moisture. The seeds were sown in MS medium (Table 15) and cultured at 25°C and 16 hours of light / 8 hours of dark cycle. After 2 to 3 weeks, when roots were formed, the roots were removed from the culture dish, and then the roots (hairy roots) were collected and analyzed for 7-DHC content by GC-MS.
[0208] [Table 15]
[0209]
[0210] GC-MS metabolic analysis was performed by mixing 10 mg of roots with 3 mL of 0.1% ascorbic acid-ethanol and 0.05 mL of 5α-cholestane to obtain root extracts. The extracts were mixed with 80% potassium hydroxide for saponification and then mixed with hexane to separate lipophilic substances. The separated lipophilic substances were derivatized with pyridine and N-methyl-N-trimethylsilyltrifluoroacetamide and then analyzed by GC-MS (gas chromatography-quadrupole mass spectrometry). For quantitative and qualitative analysis, calibration curves calculated from standard materials were used.
[0211] As a result, 7-dehydrocholesterol was not detected in the roots of WT tomatoes, but 7-dehydrocholesterol was detected in the T3 generation #3 strain (3-14-29) and #7 strain (7-1-15), with concentrations of 1.3 μg / g and 1.0 μg / g, respectively. Fig.28 ).
[0212] Example 5.3. Selection of antibiotic-free subjects in the T2 generation
[0213] In order to select those without antibiotic resistance from the T2 generation #3-14 strain (D100-3-14) and #7-1 strain (D100-7-1) obtained in Example 4, the expression of antibiotic resistance genes in the mRNA of the subjects was confirmed by RT-PCR.
[0214] The results confirmed that 5 subjects in the #3-14 strain (D100-3-14) and 11 subjects in the #7-1 strain (D100-7-1) were free of antibiotic resistance ( Fig.23 ).
[0215] Among the subjects selected as non-antibiotic resistant subjects, subjects #3-14-29 and #7-1-15 were examined for DWF5 gene editing.
[0216] The results are as follows Fig.24 and Fig.25 As shown, it was confirmed that the nucleotide sequence of the object was different from that of wild-type (WT) tomato ( Fig.24 ), and the amino acid sequence is also different from that of wild-type (WT) tomato due to the deletion of the sequence corresponding to exon 6 ( Fig.25 ).
[0217] Example 5.4. Confirmation of T2 generation phenotype and seed production
[0218] The phenotypes and seed production of the #3-14 strain (D100-3-14) and #7-1 strain (D100-7-1) of the T2 generation obtained in Example 4 were examined. Specifically, when only the DWF5 gene (DWF5-1, SEQ ID NO: 63) mainly expressed in the fruit was deleted, there were no significant differences in the phenotypes of the fruit, leaves, and stems compared to the wild-type tomato ( Fig. 27 ). Therefore, in the present invention, by deleting only the DWF5-1 (SEQ ID NO: 63) gene, tomatoes that can compensate for the seed production problem and induce provitamin D3 enrichment can be produced.
Claims
1. A transformed tomato containing a high concentration of 7-dehydrocholesterol of the following formula 1: [Formula 1] 2. The transformed tomato according to claim 1, wherein the fruit and root of the tomato contain high concentrations of 7-dehydrocholesterol.
3. The transformed tomato according to claim 1, wherein the concentration of 7-dehydrocholesterol is 0.01 mg to 1.5 mg per 100 g weight. 4 . The transformed tomato according to claim 1 , wherein the transformed tomato is genetically modified to reduce the expression or activity of the DWF5-1 gene or DWF5-1 protein compared to wild-type tomatoes. The transformed tomato according to claim 4 , wherein the DWF5-1 gene comprises the nucleic acid sequence SEQ ID NO:
63. The transformed tomato according to claim 4 , wherein the genetic modification is induced by modification of the nucleic acid sequence of the DWF5-1 gene.
7. The transformed tomato according to claim 6, wherein the modification of the nucleic acid sequence comprises a sequence different from that of the wild-type tomato by substitution, deletion or insertion.
8. The transformed tomato according to claim 4, wherein the tomato is further genetically modified to reduce the expression or activity of the CPD gene or CPD protein. 9 . The transformed tomato according to claim 8 , wherein the CPD comprises the nucleic acid sequence SEQ ID NO:
5.
10. The transformed tomato according to claim 8, wherein the genetic modification is induced by modification of the nucleic acid sequence of the CPD gene. 11 . The transformed tomato according to claim 8 , wherein the tomato is further genetically modified to reduce the expression or activity of the SMT1 gene or SMT1 protein. 12 . The transformed tomato according to claim 11 , wherein the SMT1 comprises the nucleic acid sequence SEQ ID NO:
7. 13 . The transformed tomato according to claim 11 , wherein the genetic modification is induced by modification of the nucleic acid sequence of the SMT1 gene. The transformed tomato according to claim 4 , wherein the transformed tomato is homozygous.
15. The transformed tomato according to claim 4, wherein the transformed tomato forms seeds.
16. A vector comprising at least one sgRNA (single-stranded guide RNA) that binds complementary to the nucleotide sequence of the DWF5-1 gene and a nucleotide sequence encoding a CRISPR (clustered regularly interspaced palindromic repeats)-related protein.
17. The vector according to claim 16, wherein the sgRNA comprises any one nucleotide sequence selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, and a combination thereof.
18. The vector according to claim 16, wherein the vector further comprises one or more sgRNAs that complementarily bind to the nucleotide sequence of the CPD gene.
19. The vector according to claim 18, wherein the sgRNA comprises any one nucleotide sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, and a combination thereof. 20 . The vector according to claim 16 , wherein the vector further comprises one or more sgRNAs that complementarily bind to the nucleotide sequence of the SMT1 gene.
21. The vector according to claim 20, wherein the sgRNA comprises any one nucleotide sequence selected from the group consisting of SEQ ID NO: 32, SEQ ID NO: 33, and a combination thereof.
22. The vector according to claim 16, wherein the CRISPR-associated protein is any one selected from the group consisting of: Cas9, Cpf1, c2c1, C2c2, Cas13, c2c3, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a, Cas8a1, Cas8a2, Cas8b, Cas8c, Csn1, Csx12, Cas10, Cas10d, Cas10, Cas10d, CasF, CasG , CasH, Csyl, Csy2, Csy3, Cse1(CasA), Cse2(CasB), Cse3(CasE), Cse4(CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, C mrl, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csxl, Csx15, Csf1, Csf2, Csf3, Csf4 and Cul966.
23. The vector of claim 22, wherein the CRISPR-associated protein is Cas9.
24. A method for producing transformed tomatoes containing high concentrations of 7-dehydrocholesterol, comprising introducing the vector according to any one of claims 16 to 23 into tomatoes using Agrobacterium.
Citation Information
Patent Citations
Greenterior plant cultivation device using culture fluid vibration
KR102800174B1
Transgenic plant and use thereof
WO2019163601A1
